What do systematic reviews say?

Continuous infusion vs forced (or pulse) infusion of thrombolytic agents

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 164 participants
  Very low

Continuous infusion vs forced (or pulse) infusion of thrombolytic agents

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 304 participants
  Very low

Intra‐arterial delivery vs intravenous delivery

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 78 participants
  Low

Continuous infusion vs forced (or pulse) infusion of thrombolytic agents

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 304 participants
  Very low

Continuous infusion vs forced (or pulse) infusion of thrombolytic agents

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 304 participants
  Very low

Intervention not reported

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  GRADE not reported

Intervention not reported

It is very uncertain whether the intervention changes vessel patency ( (very low certainty).

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  OR 1.2 [0.39, 3.69]
  1 study · 70 participants
  Very low

Intervention not reported

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Low

Intervention not reported

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes major bleeding ( (very low certainty).

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  OR 0.25 [0.01, 4.9]
  1 study · 70 participants
  Very low

Intra‐arterial delivery vs intravenous delivery

Intra‐arterial delivery may leads to higher vessel patency ‐ radiological success ‐ complete (to end of treatment) compared with intravenous delivery (low certainty).

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  OR 13.22 [2.79, 62.67]
  1 study · 40 participants
  Low

Intra‐arterial delivery vs intravenous delivery

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 78 participants
  Very low

Intra‐arterial delivery vs intravenous delivery

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 78 participants
  Very low

Intra‐arterial delivery vs intravenous delivery

It is very uncertain whether intra‐arterial delivery changes major bleeding (up to 6 months) compared with intravenous delivery (very low certainty).

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  OR 0.12 [0.01, 2.53]
  1 study · 40 participants
  Very low

High‐dose vs low‐dose regimens of thrombolytic agents

• Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 302 participants
  Very low

Dornase alfa vs alternate days

Dornase alfa daily showed no clear difference in mean relative percentage in quality of life score at 3 months compared with alternate days (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.01
  43 participants
  Low

Dornase alfa vs alternate days

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  43 participants
  Low

Dornase alfa vs alternate days

Dornase alfa daily showed no clear difference in mean relative percentage change in FEV1 (L) at 3 months compared with alternate days (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 2
  43 participants
  Low

Dornase alfa vs alternate days

Dornase alfa daily showed no clear difference in mean relative percentage in FVC (L) at 3 months compared with alternate days (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.03
  43 participants
  Low

Intervention not reported

The intervention probably leads to lower need for surgical closure of PDA (during hospital stay) (moderate certainty).

• Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants 2020 · Cochrane Headline outcomes only
  RR 0.46 [0.22, 0.96]
  7 studies · 925 participants
  Moderate